Alternative Diagnosis for Many Referred for Optic Neuritis

Share this content:
Alternative Diagnosis for Many Referred for Optic Neuritis
Alternative Diagnosis for Many Referred for Optic Neuritis

FRIDAY, Dec. 8, 2017 (HealthDay News) -- Almost 60 percent of patients referred for acute optic neuritis have an alternative diagnosis, according to a study published online Dec. 7 in JAMA Ophthalmology.

Leanne Stunkel, M.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a retrospective clinic-based cross-sectional study of new patient encounters to examine the incidence of and characterize factors contributing to overdiagnosis of acute optic neuritis. Data were included for 122 patients referred for acute optic neuritis at a neuro-ophthalmology clinic. Definite diagnosis was determined by neuro-ophthalmologists; the Diagnosis Error Evaluation and Research taxonomy tool was applied to categorize diagnostic errors for patients with alternative diagnoses.

The researchers found that 40.2 percent of the patients were confirmed to have optic neuritis and 59.8 percent had an alternative diagnosis. Headache and eye pain, functional visual loss, and other optic neuropathies were the most common alternative diagnoses. Eliciting or interpreting critical elements of history was the most common diagnostic error, which occurred in 33 percent of patients with alternative diagnoses. Errors weighing or considering alternative diagnoses, errors weighing or interpreting physical examination findings, and misinterpreting diagnostic test results were also common errors (32, 21, and 15 percent, respectively).

"Understanding pitfalls leading to overdiagnosis of optic neuritis may improve clinicians' diagnostic process," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer

Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer

Atezolizumab plus nab-paclitaxel prolongs progression-free survival in metastatic disease

Diagnostic Strategy Can Rule Out PE in Pregnant Women

Diagnostic Strategy Can Rule Out PE in Pregnant ...

Strategy includes clinical probability assessment, D-dimer, lower-limb compression ultrasound, CTPA

is free, fast, and customized just for you!




Already a member?

Sign In Now »